Atrium Health's Levine Cancer Institute - Charlotte (Main)

Atrium Health

Charlotte, NC

Sorting 1 by

Accepting patients

KarMMa-2

A Phase 2, Multi-Cohort, Copen-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma (KARMMA-2)
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2
  • Has results